| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d139f42bece399a108a6dea464eb053d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_97fe0d11059b79b5b65f3a9772c7f9c7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_35aadf3b6528f959f481005238797931
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3838e65b8b8d0ba4e929b2ffa98a73dd |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N1-36 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61N1-0531
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-42
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-217
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B5-0006
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5513 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61N1-36 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61N1-05
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate |
2017-01-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cc9d01973262b2fc39dd9cf5e846252b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_49fae42f903540c1a49ea4f7d5167684
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1e9ba4560d0ac74eb90d677511c27f21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9525379439e17be65c87bdc037a715a6 |
| publicationDate |
2017-11-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2017326356-A1 |
| titleOfInvention |
Methods for treating psychiatric disorders |
| abstract |
Methods for treating subjects afflicted with a psychiatric disorders [e.g., autism spectrum disorder (ASD), schizophrenia, and/or depression] are described herein. More particularly, the present invention relates to a method for treating a subject afflicted with or at risk for developing a psychiatric disorder (e.g., ASD, of which autism is a particular example) that calls for selecting a subject afflicted with or at risk for developing the psychiatric disorder based in part on previous in utero exposure to maternal immune activation (MIA) and treating the subject by administering pharmacological agents or implementing optogenetic tools or chemogenetic tools that correct dysregulated neuronal excitation/inhibition (E/I) ratios in cortical patches of the subject wherein the E/I ratio is dysregulated. A subject may also be selected for treatment using methods described herein based on the presence or detection of cortical patches having dysregulated neuronal E/I ratios. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020146610-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3702448-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020178226-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11389509-B1 |
| priorityDate |
2016-01-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |